-
-
-
-
-
-
-
Raymond James on Bristol-Myers Squibb Co. (BMY): 'we do not view the ZEPHYR data as signaling a risk to Cobenfy across indications'
-
-
-
-
-
-
-
Bristol Myers Squibb drug shows survival benefit in cancer trials
-
-
-
-
-
-
-
Bernstein SocGen on Bristol-Myers Squibb Co. (BMY): 'Hengrui deal highlights acceleration possibilities in China'
-
-
-
-
-
-
-
Bristol-Myers Squibb (BMY) Tops Q1 EPS by 16c; reaffirms guidance
-
-
-
-
-
-
-
Bristol Myers Squibb Evolves and Expands Standing in the Gaap To Advance More Equitable Care in Multiple Myeloma As Program Marks Ten Years
-
-
-
-
-
-
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $70 at Jefferies: SUCCESSOR-2 interim validates CELMoD strategy
-
-
-
-
-
-
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $75 at Piper Sandler
-
439,065 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

